On Thursday, Chimerix Inc (NASDAQ:CMRX)’s shares inclined 7.19% to $8.95.
Chimerix (CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, announced that its Phase 3 SUPPRESS trial of brincidofovir in patients undergoing hematopoietic cell transplantation (HCT) did not achieve its primary endpoint for the prevention of clinically significant cytomegalovirus (CMV) infection through Week 24 after transplant.
During the on-treatment period through Week 14 after HCT, fewer patients in the brincidofovir arm had a CMV infection, consistent with the positive antiviral effect of the compound seen in the Phase 2 study. However, during the 10 weeks off treatment from Week 14 to Week 24, there was an increase in CMV infections in the brincidofovir arm compared to the control arm. There was also a non-statistically significant increase in mortality in the brincidofovir arm compared to the control arm.
Preliminary analysis suggests that the primary endpoint failures in both the prevention of CMV infections and mortality in the brincidofovir arm were driven by confirmed cases of graft-versus-host-disease (GVHD), which resulted in a significantly higher use of corticosteroids than in the control arm. Both GVHD and use of corticosteroids are risk factors for “late” CMV infection that occurs after discontinuation of the antiviral in HCT recipients.
The rate of study drug discontinuation for gastrointestinal events was <10%, comparable to that observed in the Phase 2 trial of brincidofovir in a similar HCT population.
Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral antivirals to address unmet medical needs in the United States. The company’s lead compounds comprise brincidofovir (CMX001), an oral nucleotide analog that is in Phase III clinical trial for the prevention of cytomegalovirus (CMV) in adult hematopoietic cell transplant recipients, in addition to treat adenovirus infection; and CMX157, a nucleotide analog for the treatment of HIV and hepatitis B virus infections.
Seadrill Ltd (NYSE:SDRL)’s shares gained 0.30% to $3.39. The market capitalization of Seadrill Ltd (NYSE:SDRL) is $1.71 billion with the total traded volume of the company is 7.61 million. Turning to market valuation, the Price-to-Earnings ratio is 1.50, the Price-to-Sales ratio is 0.35 and the Price-to-Book ratio is finally 0.16. The beta ratio has a value of 1.64.
Seadrill Limited, an offshore drilling contractor, provides offshore drilling services to the oil and gas industry worldwide. The company operates through Floaters and Jack-up Rigs segments.
Diamond Offshore Drilling Inc (NYSE:DO)‘s shares surged 1.20% to $21.10. The last trading range of Diamond Offshore Drilling Inc (NYSE:DO) ranges between $20.59 and $21.27. The EPS of the company stands at $0.51. The 52-week range shows that the stock reached higher at $37.56 while its lower range is $16.51 in the last 52-weeks. The average volume of the company is at 2.25 million with the Outstanding Shares of 137.16 million. The market capitalization of the company is $2.89 billion. The Beta of the company stands at 1.35 with the RSI (Relative Strength Index) of 47.68.
Diamond Offshore Drilling, Inc. provides contract drilling services to the energy industry worldwide. The company provides services in floater market, such as ultra-deepwater, deepwater, and mid-water; and non-floater or jack-up market.
